Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$MNGA Nice reversal starting here.
Based on twitter feed and Stocktwitts, there's a pretty large short position here.
This is not a stock to be short with Q3 coming up. With last year's revenue in Q3 totaling $146,000, it will be a blowout Q.
lol "Sabsiosa"
Spreading FUD seems to be your only purpose here.
No need for a reverse split since they're not on a major exchange (yet) in CA or in the US
yep- that's my plan for now anyway.
True MisterEC- and I expect the BOD made the decision because Q3 will be another disaster.
So while I see a positive long term, I'm not a buyer here.
Single digits are entirely possible with a rough Q3, probably a continued lack of guidance, no "oar in the water" as you say, and eoy tax loss selling.
$DDD doing the right thing in Avi's departure.
As I said before...
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113855944&txt2find=AVI
$DDD Avi Reichental stepping down as CEO.
I'm all for it!
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113855944&txt2find=AVI
They're not going to tell me anything - it would have to come out in a pr and/or filing.
So I can't say.
If the Sysmex deal is finalized and they begin commercialization, then that's where the stock will be headed.
Big seller on .10 today.
Well said.
$CANF Anyone have any thoughts on this one?
Had interesting news yesterday, New Study Demonstrates CF602 Mechanism of Action to Improve Sexual Dysfunction
But closed down during the continuation of "PHARMAGEDDON".
Recent capital raise at $4.35 , trading $3.48 near bottom of 3 month channel.
$VRX short squeeze potential - management to address Citron allegations Monday
http://finance.yahoo.com/news/valeant-pharmaceuticals-hold-investor-conference-183700513.html
$MNGA - this isn't a "one and done" contract either. It's RECURRING revenue.
Love this super growth company- $2 coming very very soon!
$DEPO 129% CAGR since 2012
And trading like a POS.
Stop triggered.
Biotech still toxic.
$DEPO - I like chart.
Looks like potential double bottom with 9/29 and today.
Took starter at $16.63 - tight mental stop set.
Did some dd and appreciate the heads up on this one.
$EYES is green
Chart really looks like it wants to get up and go here-
Looking forward to numbers tomorrow.
All indications are for another strong Q.
Arcam reports tomorrow- should be interesting to see the numbers- all indications look very positive.
ARCM.ST / AMAVF
$XXII: Canada's newly elected Prime Minister, Justin Trudeau. states will make moves to legalize Cannabis "right away"
On marijuana
Trudeau has said he would start moves to legalise it “right away”, based on the Colorado model.
http://www.theguardian.com/politics/2015/oct/20/justin-trudeau-canada-new-prime-minister-liberals …
$XXII up another 12% today
This is an FDA play on nicotine regulation (see video in linked post).
Submission pending- by eoy per management.
Article: Snowden keynote at Bard conference stresses privacy
“Privacy isn't about something to hide, it's about something to lose”
http://www.scmagazine.com/snowden-keynote-at-bard-conference-stresses-privacy/article/447799/?utm_source=dlvr.it&utm_medium=twitter
Another great day.
have a great weekend all
$OREX + 8% on highest volume in > 3 months and no news
Funds buying recently
http://www.insidermonkey.com/blog/orexigen-therapeutics-inc-orex-and-spectranetics-corp-spnc-billionaires-klarman-and-cohen-snapped-up-these-healthcare-stocks-376646/
Q3 should be interesting
Looking for ongoing relationship with Sysmex.
it's been very quiet lately- at least we know management isn't promoting the stock to sell it, lol.
$XXII - For those who haven't seen this video, the cigarettes the New England Journal of Medicine used in the study were XXII ciggs, and were paid for by the FDA.
http://www.nejm.org/action/showMediaPlayer?doi=10.1056/NEJMsa1502403&aid=NEJMsa1502403_attach_1
The FDA stopped American Spirit from advertising as a lower risk or modified risk product. Now, this trial in the video bodes well for XXII as they apply to FDA to be the ONLY company in the world with the government's approval to advertise as a modified risk tobacco product or smoking cessation aid.
The MJ news today is nothing compared to what big tobacco (or big pharma?) will pay for XXII as a smoking reduction aid that has FDA approval and ultimately covered by insurance as a product with ZERO side effects of psych. drugs like Chantix.
So I think about a pharma or big tobacco partnership or buyout - it's much bigger than the MJ potential here.
$XXII on the move again.
Big potential for this one with FDA submission for a modified/reduced risk tobacco product pending by eoy.
There's been so many new contracts/deals announced since Q2 that will be immediately accretive it's hard to say. It will be a new record Q- that much seems certain.
$MNGA Q3 revenue was a mere $146,000 last year. A BLOWOUT QUARTER is on the horizon.
70k share buy at $1.19
11:15 am
http://www.nasdaq.com/symbol/hotr/time-sales
$MNGA: New contracts & more revenue comes almost daily. Now expanding in CA & will be a $2+ stock soon: http://finance.yahoo.com/news/additional-industrial-gas-supplier-california-130000376.html …
Difference now is they have much stronger case with FDA-funded study that concluded:
“in the 30 days following the trial, smokers of very low nicotine cigarettes (XXII’s Spectrum cigarettes)reported they attempted to quit smoking at a rate double that of participants who smoked cigarettes with 15.8 mg/gram nicotine (34.7% vs. 17%)”
And these were smokers who were not planning to quit.
So getting pharma partner may be much closer now.
Incidentally- I have MBA in healthcare management and am former hospital administrator. Docs would prescribe ciggs if research backs up use and FDA approves.
And on a more personal note- I'm a former smoker. Quitting was the hardest thing I ever did in my life- and I mean that literally. it took 8 or 10 attempts, but I finally quit for good a decade ago. Anything that makes current smokers who were not planning to quit want to try quit 2X more than a control group- is a good thing.
Drugs like Chantix can be dangerous- big increase in suicide risk/etc. that ciggs would not have. FDA could easily smile on XXII.
$XXII a Pharma Play?
Given the results published in the NEJM, I think there's potential down the road for insurance companies to pay for XXII ciggs. The FDA are in the driver's seat regarding regulation of the drug. It's possible (but would take clinical trials with a big pharma partner I would think) for the ciggs to be prescribed like Chantix is, as a smoking cessation drug, with insurance companies reimbursing.
So big pharma may find XXII attractive as well, not just big tobacco
$SITO Mobile CEO: No Negative Impact from iOS 9
http://microcapresearch.com/sito-update/
$XXII Read why George Soros and Goldman Sachs have been buying
Positive Catalysts Coming to 22nd Century Group (XXII)
$XXII + 10% on volume
The cigarettes used in the study published by the New England Journal of Medicine referenced in this video and paid for by the FDA are from XXII:
http://www.nejm.org/action/showMediaPlayer?doi=10.1056/NEJMsa1502403&aid=NEJMsa1502403_attach_1
XXII could be the FIRST and ONLY tobacco company to have FDA approval to advertise their cigarettes as a smoking cessation aid.
FDA application pending: http://finance.yahoo.com/news/22nd-century-announces-strategic-hire-125900089.html
XXII "is committed to working collaboratively with the FDA to demonstrate that our Very Low Nicotine cigarettes and our Low Tar-to-Nicotine Ratio cigarettes are legitimate – and enormously important – modified risk tobacco products.”
So- how much might Philip Morris or Reynolds Tobacco pay for XXII which is heavily patented in plant genetics....? Especially after FDA has pulled some of their "modified risk" products from the shelves?
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm462407.htm
many many many times current market cap.
"I don't recall ever see them posted on a company's homepage as you stated"
That's because it's not done.
But I think GGG's web site should have a link to financials- especially now that they'll be gaining > $1 million in revenue from Graphene Labs, plus (what evidence suggests will be) strong sales from graphene and other filaments.
Black Magic 3D on Amazon: http://www.amazon.com/gp/aag/main?ie=UTF8&asin=&isAmazonFulfilled=1&isCBA=&marketplaceID=ATVPDKIKX0DER&orderID=&protocol=current&seller=A2E2WDJUDG3SNW&sshmPath=